Close Menu
Home » Editas Medicine to Provide Broad Institute With up to $125M in CRISPR Funding

Editas Medicine to Provide Broad Institute With up to $125M in CRISPR Funding

Jun 11, 2018
|
staff reporter

NEW YORK (GenomeWeb) — CRISPR-based therapeutics developer Editas Medicine has agreed to provide up to $125 million in research funding to the Broad Institute in exchange for the exclusive right to be the first to negotiate for licenses to genome-editing inventions that arise from the sponsored research.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Hundreds and Hundreds Retracted

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

Guilty Plea in Kickback Case

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

Florida Bill Moves Ahead

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

Science Presents Studies Into Disease-Causing Mutations Among Bone Marrow Donors; Links Between Heavy Drinking, Other Disease

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.

What's Popular?

In Business News

  1. Revocation of Broad Institute CRISPR Patent Upheld in Europe

  2. JP Morgan Healthcare Day 3: Exact Sciences, NanoString, Natera, Horizon, Accelerate Dx, GenMark, More

  3. JP Morgan Healthcare Day 2: 10x Genomics, GenapSys, Caris, Adaptive Bio, Danaher, Agilent, Luminex

  4. JP Morgan Healthcare Day One: Qiagen, Guardant Health, Bio-Rad, Hologic, Myriad Genetics

  5. Illumina Targets Single-Cell, Oncology Applications With New NextSeq Platform

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.